Skip to content
Peptigraph home
Shop Peptides50% off*

How AOD-9604 Works: Mechanism and Pharmacology

How AOD-9604 works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.

Medical review pendingHGH fragment analogUpdated
Class
HGH fragment analog
FDA status
Not approved
research chemical
Routes studied
oral; mini-osmotic pump; intraperitoneal
Half-life
[pending]
by route, with source

How long it acts

No published half-life found for AOD-9604 (PubMed search, 11 Oct 2026)

Which receptor AOD-9604 does and does not use

In cell assays and obese-mouse work, AOD9604 did not compete for the growth hormone receptor and did not drive cell proliferation the way growth hormone did.[3]

In beta-3 adrenergic receptor knockout mice the weight and lipolysis effects of long-term treatment did not appear, which points to that receptor pathway being involved in mice.[4]

What it changed in mouse and rat fat tissue

In obese mice, treatment raised the expression of beta-3 adrenergic receptor RNA, the main lipolytic receptor of fat cells, back toward lean-mouse levels.[4]

The authors of that mouse paper concluded the lipolytic effects are not mediated directly through the beta-3 receptor even though expression rose, so the exact route is left open.[4]

A rat clamp study found no adverse change in insulin sensitivity with AOD9604, unlike intact growth hormone.[5]

What is still unknown in people

No label exists for this peptide: the Drugs@FDA lookup for AOD-9604 returned no match on 2 October 2026, so there is no regulator-written Mechanism of Action section to quote.

Calculated from source s2-legal/api.fda.gov/drugsfda-aod-9604.txt; date 2026-10-02; matches 0; label moa sections 0. Formula: Drugs@FDA matches = 0, so label mechanism sections = 0

Every mechanism statement on this page comes from the 3 animal and cell papers listed, and the evidence file records no human pharmacokinetic or mechanism study with numbers.

Calculated from mechanism abstracts 3; species rat, mouse, cell assay; human mechanism studies 0. Formula: mechanism sources = 3, all non-human; human mechanism studies = 0

Related peptides

AOD-9604 vs TesamorelinGHRH analogAOD-9604 vs MOTS-cMitochondrial-derived peptideAOD-9604 vs 5-Amino-1MQNNMT inhibitor (not a peptide)AOD-9604 vs RetatrutideGLP-1 / GIP / glucagon triple agonist

Common questions

How long does AOD-9604 act in the body?

We found no published half-life for AOD-9604 (PubMed search, 11 Oct 2026), so how long it acts is unknown.

Does AOD-9604 work like growth hormone?

In the mouse paper the fragment reduced weight gain like growth hormone but did not bind the growth hormone receptor.[3]

What is the mechanism of AOD-9604 lipolysis?

Mouse work links the lipolytic effect to the beta-3 adrenergic pathway, but the authors say the action is not mediated directly through that receptor.[4]

More on AOD-9604

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.BenefitsClaimed benefits next to what published studies measured.

Sources

  1. 1PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  3. 3Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
  4. 4The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.Endocrinology · 2001PMID 11713213Accessed 2 Oct 2026
  5. 5Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026

Found an error? Report a correction.